After realizing that there were no anatomically correct training models in thoracic surgery, it was clear in 2022 that MD2B LifeScience The (Bio) Phantom Company, or MD2B for short, would be founded. This initially took place as a start-up or spin-off of Otto von Guericke University Magdeburg in the field of medical technology until 2025, when it was separated from the university.
Over time, other biophantoms were also developed outside the field of thoracic surgery. In addition, services such as cell-based compatibility tests are offered through the use of standardized 3D tissue models.
The young team currently consists of ten motivated members who are helping to shape the MD2B product line.